Aquestive Therapeutics is the undisputed leader in developing and delivering medications via film, through PharmFilm® technology. Building on this success, we have established a robust portfolio of treatments for CNS disorders and are advancing a late-stage pipeline with promising treatments for complex conditions.
Our investigational medicines can offer simple new ways for patients and caregivers to use proven and trusted molecules. Our late-stage pipeline includes several investigational treatments for CNS conditions, where patients face great difficulty in using medication because of the impact of their disease.1 Looking ahead, we see even greater potential for PharmFilm® technology to improve patient treatment and are working to deliver complex molecules, proteins, and peptides on oral film with newer prodrugs and technologies.
*Aquestive has received conditional acceptance of the use of this trade name, which is subject to final FDA review and acceptance
†Subject to review, evaluation, and approval of the FDA
1. Holsti M, Dudley N, Schunk J, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med. 2010;164(8):747–753.
2. Fischer D, Vander Leek TK, Ellis AK, Kim H. Anaphylaxis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):54
3. Wood RA, Camargo CA Jr, Lieberman P, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014 Feb;133(2):461-467.
4. Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(4):1075-1083.